ReviewInfection2023
Reactive arthritis occurring after COVID-19 infection: a narrative review.
Review in Infection, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 4 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- Immunoinflammatory evidence of rheumatoid arthritis caused by COVID-19.Biological research · 2025Pooled it
- Sjögren's Syndrome and Ankylosing Spondylitis Association: A Case-Based Review.Current rheumatology reviews · 2025Pooled it
- Bone Mineral Density, Bone Biomarkers, and Joints in Acute, Post, and Long COVID-19: A Systematic Review.Viruses · 2024Pooled it
- COVID-associated arthritis after severe and non-severe COVID-19: A systematic review.Immunity, inflammation and disease · 2023Pooled it
- Successful Treatment of Post-SARS-CoV-2 Infection Reactive Arthritis With Secukinumab: A Case Report and Literature Review.Clinical case reports · 2025Article
- Parsonage-Turner Syndrome Following AstraZeneca COVID-19 Vaccination.Current drug safety · 2025Article
- Blockade of endothelin receptors mitigates SARS-CoV-2-induced osteoarthritis.Nature microbiology · 2024Article
- Diagnostic considerations in the clinical management of sudden swelling of the knee: a case report and review of the literature.Journal of medical case reports · 2024Review
- Molecular mimicry and autoimmunity in the time of COVID-19.Journal of autoimmunity · 2023Review
- Arthritis after SARS-CoV-2 infection: reactive arthritis or virally mediated arthritis?Infection · 2023Article
- Post-Acute COVID-19 Joint Pain and New Onset of Rheumatic Musculoskeletal Diseases: A Systematic Review.Diagnostics (Basel, Switzerland) · 2023Review
- Axial spondylarthritis following COVID-19 infection.BMJ case reports · 2023Article
- Is recovery just the beginning? Persistent symptoms and health and performance deterioration in post-COVID-19, non-hospitalized university students-a cross-sectional study.Biology methods & protocols · 2023Article
- Cutaneous and rheumatological manifestations of reactive arthritis: A case report.Clinical case reports · 2022Article
- Post-COVID-19 reactive arthritis.Clinical rheumatology · 2022Article
- Speculation on the pathophysiology of musculoskeletal injury with COVID-19 infection.Frontiers in medicine · 2022Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeReactive arthritis is acute aseptic arthritis occurring 1 to 4 weeks after a distant infection in a genetically predisposed individual. It may occur after COVID-19 infection. We summarize, in this article, the current findings of reactive arthritis following COVID-19 infection.
methodsA literature search has been performed from December 2019 to December 2021. We included case reports of reactive arthritis occurring after COVID-19 infection. We collected demographic, clinical, and paraclinical data.
resultsA total of 22 articles were reviewed. There were 14 men and 11 women with a mean age of 44.96 + 17.47 years. Oligoarticular involvement of the lower limbs was the most frequent clinical presentation. The time between arthritis and COVID infection ranged from 6 to 48 days. The diagnosis was based on clinical and laboratory findings. The pharmacological management was based on non-steroidal anti-inflammatory drugs in 20 cases. Systemic or local steroid therapy was indicated in 13 patients. Sulfasalazine was indicated in two cases. Alleviation of symptoms and recovery were noted in 22 cases. The mean duration of the clinical resolution was 16 + 57 days.
conclusionThe diagnosis of reactive arthritis should be considered in patients with a new onset of arthritis following COVID-19 infection. Its mechanism is still unclear.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.